“In terms of clinical trials, I think it's still going to take a few years to get past the clinical trial realm,” Gibson said. “But I think we can reduce the cost of finding a drug and bringing it into the clinic from five or six years and hundreds of millions of dollars to maybe just $10 million or $20 million in one or two years.”
Recursion is currently developing a new drug to treat cavernous malformations. Although this neurovascular disease is not widely known, it affects six times as many people in the United States as cystic fibrosis, Gibson said. He said that until Recursion adopted his AI-focused approach, there was no clear path to developing drugs to successfully combat the disease. The new treatment has nearly completed phase 2 trials.
Gibson said he thinks using this new technology to map biology will become commonplace in the biopharmaceutical industry within five to 10 years.
“Think of it like Google Street View running around and taking pictures of everything,” he said. “We have microscopes that take tens of millions of pictures of cells every week, and we use many of the same AI algorithms to transform those images into mathematical representations of biology, which We think there are some really interesting secrets that could be uncovered.”
Sign up now Because CNBC Investment Club tracks Jim Cramer's every move in the markets.
Disclaimer CNBC Investing Club Charitable Trust owns shares of Nvidia.